Recombinant Lactobacillus with decreased lipoteichoic acid to reduce inflammatory responses
    9.
    发明授权
    Recombinant Lactobacillus with decreased lipoteichoic acid to reduce inflammatory responses 有权
    重组乳酸杆菌与脂磷壁酸减少以减少炎症反应

    公开(公告)号:US09340792B2

    公开(公告)日:2016-05-17

    申请号:US13805037

    申请日:2011-06-16

    摘要: Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease.

    摘要翻译: 提供了治疗或预防炎症性疾病的方法和组合物。 本发明的组合物包含经遗传修饰以减少细胞表面上脂磷壁酸显示的重组细菌。 本发明的方法包括向受试者施用经修饰以减少细胞表面上的脂磷壁酸显示的重组细菌。 重组细菌的施用促进期望的治疗反应。 重组细菌可以以单一剂量或一系列剂量施用。 本发明的方法可用于治疗或预防各种炎性疾病,包括例如治疗或预防炎症性肠病,结肠炎或克罗恩氏病。